期刊文献+

Smad4和VEGF在人非小细胞肺癌组织中的表达及其相关性分析 被引量:9

Evaluation of Smad4 and VEGF expression and their correlation in human non-small cell lung cancer
下载PDF
导出
摘要 目的检测Smad4和VEGF蛋白在非小细胞肺癌(NSCLC)组织中的表达情况并分析其表达的相关性。方法采用免疫组织化学染色检测71例原发性NSCLC及对应癌旁组织中Smad4、VEGF蛋白的表达情况,分析Smad4蛋白表达与NSCLC不同临床病理特征的相关性以及其与VEGF蛋白表达的相关性。结果 Smad4和VEGF蛋白在NSCLC组织中的阳性表达率为57.7%(41/71)和71.8%(51/71),而对应癌旁组织中两者的表达率为77.5%(55/71)和49.3%(35/71),差异具有统计学意义(χ2=6.303,P=0.012;χ2=7.548,P=0.006)。Smad4蛋白表达与肿瘤分化(χ2=9.987,P=0.002)和TNM分期(χ2=5.943,P=0.015)有关。另外,NSCLC组织中Smad4与VEGF蛋白表达呈显著负相关(r=-0.638,P=0.009)。结论 NSCLC组织中Smad4蛋白表达缺失,并与恶性临床病理特征密切相关,且Smad4与VEGF蛋白表达呈显著负相关,提示Smad4缺失可能通过VEGF促进肿瘤新生血管形成和肿瘤进展。 Objective To investigate the expression of Smad4 and VEGF and their correlation in human non-small cell lung cancer(NSCLC)tissues.Methods 71 samples of surgically resected NSCLC and matched normal tumor-adjacent tissues were subjected to immunohistochemistry for Smad4 and VEGF protein.Correlation between Smad4 protein expression and different clinicopathological features in NSCLC and its association with VEGF protein were analyzed.Results The positive expression rate of Smad4 and VEGF protein were 57.7%(41/71)and 71.8%(51/71),respectively,in NSCLC tissues,while their positive expression rates were 77.5%(55/71)and 49.3%(35/71),respectively,in matched normal-adjacent tissues.The difference was significantly(χ^2=6.303,P=0.012;χ^2=7.548,P=0.006).The expression of Smad4 protein was significantly correlated with tumor differentiation(χ^2=9.987,P=0.002)and TNM tumor stage(χ^2=5.943,P=0.015).Otherwise,Smad4 was inversely correlated with VEGF protein in NSCLC tissues(r=-0.638,P=0.009).Conclusion Loss of Smad4 protein expression is observed in NSCLC and its low-expression is associated with poor clinicopathological parameters.Furthermore,Smad4 is inversely correlated with VEGF protein in NSCLC,suggesting Smad4 loss may promote neoangiogenesis and tumour progression through VEGF in NSCLC.
机构地区 唐山市工人医院
出处 《中国实验诊断学》 2014年第11期1781-1784,共4页 Chinese Journal of Laboratory Diagnosis
关键词 SMAD4 VEGF 非小细胞肺癌 肿瘤进展 Smad4 VEGF non-small cell lung cancer tumous progression
  • 相关文献

参考文献15

  • 1Iacobuzio-Donahue CA, Fu B, Yachida S, et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in pa- tients with pancreatic cancer[J]. J Clin Oncol, 2009, 27 (11): 1806.
  • 2Shin SH,Kim SC, Hong SM, et al. Genetic alterations of K-ras, p53,c-erbB-2,and DPC4 in pancreatic ductal adenocarcinoma and their correlation with patient survival[J]. Pancreas, 2013,42 (2) : 216.
  • 3Fleming NI, Jorissen RN, Mouradov D, et al. SMAD2, SMAD3 and SMAD4 mutations in eoloreetal cancer[J]. Cancer Res,2013, 73(2) :725.
  • 4Voorneveld PW, Kodaeh LL,Jaeobs R J, et al. Loss of SMAD4 Al- ters BMP Signaling to Promote Coloreetal Caneer Celt Metastasis via Activation of Rho and ROCK[J]. Gastroenterology, 2014,147 (1) :196.
  • 5Nakayama M, Nakayama A, van Lessen M, et al. Spatial regula- tion of VEGF receptor endocytosis in angiogenesis[J]. Nat Cell Biol, 2013,15(3) : 249.
  • 6Huang X, Huang S, Zhang F, et al. Lentiviral-mediated Smad4 RNAi promotes SMMC-7721 cell migration by regulation of MMP-2,VEGF and MAPK signaling[J]. Mol Med Rep, 2010,3 (2) :295.
  • 7Ignatius Ou SH, Zell JA. The applicability of the proposed IASI.C staging revisions to small cell lung cancer (SCLC) with compari- son to the current UICC 6th TNM Edition[J]. J Thorac Oncol, 2009,4(3) : 300.
  • 8张竞,涂康生,周振宇,郑鑫,高洁,姚英民,刘青光.GRAMD4在肝细胞癌中的表达及临床意义[J].细胞与分子免疫学杂志,2013,29(2):190-193. 被引量:10
  • 9Siegel R,Naishadham D,Jemal A. Cancer statistics, 2013[J]. CA Cancer J Clin,2013,63(1) :11.
  • 10仇铁峰,丁明,李献文,金建华.Skp2 mRNA在肺癌中的表达及意义[J].海南医学院学报,2014,20(3):327-330. 被引量:2

二级参考文献27

  • 1Hai-XiaQin,Ke-JunNan,GuangYang,ZhaoJing,Zhi-PingRuan,Chun-LiLi,RuiXu,HuiGuo,Chen-GuangSui,Yong-ChangWei.Expression and clinical significance of TAp73α, p53, PCNA and apoptosis in hepatocellular carcinoma[J].World Journal of Gastroenterology,2005,11(18):2709-2713. 被引量:12
  • 2Aristidis M,Serhiy S,Carl-Henrik H.Smad regulation in TGF-β signal transduction.J Cell Science,2001,114:4359-4369.
  • 3Johnson GL,Lapadat R.Mitogen activated protein kinase pathways mediated by ERK,JNK and p38 protein kinases.Science,2002,298:1911-1912.
  • 4Nancy D,Andrei VB,Carlos LA.Autocrine transforming growth factor-β signaling mediates smad-independent motility in human cancer cells.J Biol Chem,2003,278:3275-3285.
  • 5Maliekal TT,Antony ML,Nair A,et al.Loss of expression,and mutation of Smad 2 and Smad4 in human cervical cancer.Oncogene,2003,22:4889-4897.
  • 6Campbell SL,Khosravi FR,Rossman KL,et al.Increasing complexity of Ras signaling.Oncogene,1998,17:1395-1413.
  • 7Greenberg AK,Basu S,Hu J,et al.Selective p38 activation in human non-small cell lung cancer.Am J Respir Cell Mol Biol,2002,26:558-564.
  • 8Xiao L,Lang W.A dominant role for the c-Jun NH2-terminal kinase in oncogenic ras-induced morphologic transformation of human lung carcinoma cells.Cancer Res,2000,60:400-408.
  • 9Fu Y,O' Connor LM,Shepherd T G,et al.The p38 MAPK inhibitor,PD169316,inhibits transforming growth factor betainduced Smad signaling in human ovarian cancer cells.Biochem Biophys Res Commun,2003,310:391-397.
  • 10Jono H,Xu H,Kai H,et al.Transforming growth factor-beta-Smad signaling pathway negatively regulates nontypeable Haemophilus influenzae-induced MUC5AC mucin transcription via mitogenactivated protein kinase (MAPK) phosphatase-1-dependent inhibition of p38 MAPK.J Biol Chem,2003,278:27811-27819.

共引文献27

同被引文献128

引证文献9

二级引证文献56

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部